FDA Clears 22nd Century Group, Inc.'s X-22 IND For Phase II-B Smoking Cessation Clinical Trial  
7/22/2011 10:50:49 AM

WILLIAMSVILLE, N.Y.--(BUSINESS WIRE)--22nd Century Group, Inc. (OTCBB: XXII), a company focused on smoking cessation and tobacco harm reduction products, today announced that the U.S. Food & Drug Administration (FDA) has cleared an Investigational New Drug (IND) Application to conduct a Phase II-B clinical trial using X-22, a prescription smoking cessation aid in development.